New Drug Target Emerges for a Dangerous Fungal Pathogen
STONY BROOK, N.Y., February 6, 2018 –
Cryptococcus neoformans is a fungal pathogen usually affecting immunocompromised patients, particularly AIDS and organ transplant patients, and is one that can be lethal. Current treatments against cryptococcosis are often not effective. Now a team of researchers led by Stony Brook University scientists Mansa Munshi and Maurizio Del Poeta in the Department of Molecular Genetics & Microbiology, have discovered a novel gene that helps understand the mechanism of survival of this pathogen in various host conditions. Their finding, published in
, may help pave the way for more effective and innovative treatments against cryptococcosis.
When C. neoformans survives in a host, disease results. In the paper, the team details how they uncovered that ceramides (a class of lipid molecules) play a role in the pathogenicity of C. neoformans. They identified a new gene within this process, called Cer1, which synthesizes ceremides. By targeting Cer1, pathogenicity in the host is altered.
Munshi and colleagues delete Cer1 from the pathogen, and a mutant form of C. neoformans is created that is completely disabled and unable to cause disease. These results have led the team to theorize that Cer1 may be a new drug target in the search for better treatments of cryptococcosis.
The research was supported in part by the National institutes of Health.
About Stony Brook University
Stony Brook University is going beyond the expectations of what today’s public universities can accomplish. Since its founding in 1957, this young university has grown to become a flagship as one of only four University Center campuses in the State University of New York (SUNY) system with more than 26,000 students and 2,600 faculty members, and 18 NCAA Division I athletic programs. Our faculty have earned numerous prestigious awards, including the Nobel Prize, Pulitzer Prize, Indianapolis Prize for animal conservation, Abel Prize and the inaugural Breakthrough Prize in Mathematics. The University offers students an elite education with an outstanding return on investment: U.S. News & World Report ranks Stony Brook among the top 50 public universities in the nation. Its membership in the Association of American Universities (AAU) places Stony Brook among the top 62 research institutions in North America. As part of the management team of Brookhaven National Laboratory, the University joins a prestigious group of universities that have a role in running federal R&D labs. Stony Brook University is a driving force in the region’s economy, generating nearly 60,000 jobs and an annual economic impact of more than $4.6 billion. Our state, country and world demand ambitious ideas, imaginative solutions and exceptional leadership to forge a better future for all. The students, alumni, researchers and faculty of Stony Brook University are prepared to meet this challenge.